EDAP TMS SA current report, Q3 FY2025

EDAP TMS SA Form 6-K Summary

Business Context and Reporting Period

EDAP TMS SA, a global leader in robotic energy-based therapies, reported unaudited consolidated financial results for the second quarter and first half of 2025 ended June 30, 2025. The company is transitioning to become a U.S. domestic filer effective January 1, 2026. The reporting period highlights a strategic pivot toward its core High-Intensity Focused Ultrasound (HIFU) business, specifically the Focal One Robotic HIFU System, while non-core ESWL and Distribution segments continue to decline.

Key Financial Metrics

Metric Q2 2025 (EUR) Q2 2024 (EUR) Y/Y Change
Total Revenue 16.0 million 15.8 million +1.6%
HIFU Revenue 8.5 million 4.8 million +76.8%
Non-Core Revenue 7.6 million 11.0 million -30.9%
Gross Profit 6.8 million 5.9 million +15.3%
Gross Margin 42.5% 37.5% +5.0 pts
Operating Loss (5.8) million (6.1) million -4.9%
Net Loss (5.6) million (6.1) million -8.2%
Cash & Equivalents (as of June 30, 2025) 16.3 million 22.8 million (Mar 31, 2025) -28.5% (QoQ)

Material Changes vs. Prior Period

  • HIFU Growth: HIFU revenue surged 76.8% year-over-year, driven by nine Focal One capital sales in Q2 2025 compared to three in Q2 2024. Net placements of Focal One systems grew 140% year-over-year.
  • Non-Core Decline: Non-core business (ESWL and Distribution) revenue declined 30.9% year-over-year, consistent with the strategic decision to focus exclusively on the HIFU platform.
  • Margin Expansion: Gross profit margin improved to 42.5% from 37.5% in the prior year, attributed to the higher-margin mix of the core HIFU business.
  • Operating Expenses: Operating expenses increased to EUR 12.6 million from EUR 12.1 million, primarily due to focused investments in the HIFU business.
  • Liquidity: Cash and cash equivalents decreased to EUR 16.3 million as of June 30, 2025, from EUR 22.8 million at the end of Q1 2025. Operating cash flow for the six months ended June 30, 2025, was negative EUR 9.2 million.

Guidance, Outlook, and Risks

  • Updated 2025 Guidance:
    • Core HIFU Revenue: Raised guidance to 26%–34% year-over-year growth (previously 16%–25%).
    • Non-Core Revenue: Expected to decline 25%–30% year-over-year (previously 20%–25%).
  • Financing: Executed a Letter of Intent for a EUR 36 million credit facility with the European Investment Bank (EIB) to accelerate HIFU growth and strategic expansion.
  • Clinical Momentum: Management cited positive outcomes from the FARP Randomized Controlled Trial and the HIFI study as drivers for future adoption.
  • Risks: Forward-looking statements are subject to risks including clinical status and market acceptance of HIFU devices, global economic instability, inflation, and geopolitical factors. The filing notes no assurance that the EIB credit facility will be finalized.

Investor Verification Checklist

  • Confirm the final execution and terms of the EUR 36 million credit facility with the European Investment Bank.
  • Monitor the trajectory of Focal One net placements to validate the raised 2025 HIFU revenue guidance.
  • Assess the sustainability of the cash burn rate given the decrease in cash reserves to EUR 16.3 million.
  • Verify the timeline for the transition to U.S. domestic filer status effective January 1, 2026.
  • Review the impact of the declining non-core business on overall revenue stability as the company pivots.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.